Why particle size should affect clinical response to inhaled therapy
Why particle size should affect clinical response to inhaled therapy
Studies with ?2-adrenergic agonists have shown that particle size and total dose are important determinants of optimum bronchodilation. Drug deposition in the airways is probably the most important factor for bronchodilation, since ?2-adrenoceptors and muscarinic M3 receptors are present mainly in the peripheral and central airways, respectively. Furthermore, clinical efficacy can be maintained while minimizing systemic exposure by selecting an appropriate particle size. Changes in lung function provide a means of monitoring the relationship between delivery of the bronchodilator and its efficacy, whereas there is no such immediate means of assessing antiinflammatory preventative therapy such as inhaled corticosteroids. Asthma is primarily an inflammatory disease but there are no simple tests to detect the accumulation of inflammatory cells and mediators. Data are presented to demonstrate the reduction of certain inflammatory markers in bronchial biopsy tissue taken from asthmatic patients after corticosteroid therapy. Measurement of inflammatory markers in both bronchial biopsy tissue and bronchoalveolar lavage samples may provide a way of monitoring the site of action and efficacy of inhaled corticosteroids in the future. Furthermore, it is envisaged that the effect of corticosteroid particle size on efficacy and systemic bioavailability may be investigated by exploiting these methods.
asthma, efficacy, particle size, lung deposition, ?2-adrenergic agonists, corticosteroids
S27-S34
Howarth, P.H.
ff19c8c4-86b0-4a88-8f76-b3d87f142a21
2001
Howarth, P.H.
ff19c8c4-86b0-4a88-8f76-b3d87f142a21
Howarth, P.H.
(2001)
Why particle size should affect clinical response to inhaled therapy.
Journal of Aerosol Medicine, 14 (1 Supplement 1), .
(doi:10.1089/08942680150506312).
Abstract
Studies with ?2-adrenergic agonists have shown that particle size and total dose are important determinants of optimum bronchodilation. Drug deposition in the airways is probably the most important factor for bronchodilation, since ?2-adrenoceptors and muscarinic M3 receptors are present mainly in the peripheral and central airways, respectively. Furthermore, clinical efficacy can be maintained while minimizing systemic exposure by selecting an appropriate particle size. Changes in lung function provide a means of monitoring the relationship between delivery of the bronchodilator and its efficacy, whereas there is no such immediate means of assessing antiinflammatory preventative therapy such as inhaled corticosteroids. Asthma is primarily an inflammatory disease but there are no simple tests to detect the accumulation of inflammatory cells and mediators. Data are presented to demonstrate the reduction of certain inflammatory markers in bronchial biopsy tissue taken from asthmatic patients after corticosteroid therapy. Measurement of inflammatory markers in both bronchial biopsy tissue and bronchoalveolar lavage samples may provide a way of monitoring the site of action and efficacy of inhaled corticosteroids in the future. Furthermore, it is envisaged that the effect of corticosteroid particle size on efficacy and systemic bioavailability may be investigated by exploiting these methods.
This record has no associated files available for download.
More information
Published date: 2001
Keywords:
asthma, efficacy, particle size, lung deposition, ?2-adrenergic agonists, corticosteroids
Identifiers
Local EPrints ID: 27153
URI: http://eprints.soton.ac.uk/id/eprint/27153
PURE UUID: a6f312b9-cc88-4784-86e7-794f45f4cd56
Catalogue record
Date deposited: 26 Apr 2006
Last modified: 15 Mar 2024 07:16
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics